Analysts’ Weekly Ratings Updates for AnaptysBio (ANAB)

Several brokerages have updated their recommendations and price targets on shares of AnaptysBio (NASDAQ: ANAB) in the last few weeks:

• 5/4/2026 – AnaptysBio was upgraded by Zacks Research from “hold” to “strong-buy”.
• 5/4/2026 – AnaptysBio had its price target lowered by Piper Sandler from $95.00 to $93.00. They now have an “overweight” rating on the stock.
• 4/28/2026 – AnaptysBio had its price target raised by Leerink Partners from $66.00 to $85.00. They now have an “outperform” rating on the stock.
• 4/25/2026 – AnaptysBio was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 4/22/2026 – AnaptysBio had its price target lowered by Barclays PLC from $79.00 to $63.00. They now have an “overweight” rating on the stock.
• 4/21/2026 – AnaptysBio had its price target lowered by UBS Group AG from $90.00 to $60.00. They now have a “buy” rating on the stock.
• 3/31/2026 – AnaptysBio had its price target raised by Piper Sandler from $67.00 to $95.00. They now have an “overweight” rating on the stock.
• 3/30/2026 – AnaptysBio had its “buy” rating reaffirmed by HC Wainwright. They now have a $66.00 price target on the stock.
• 3/25/2026 – AnaptysBio was upgraded by Truist Financial Corporation to “hold”.
• 3/17/2026 – AnaptysBio had its price target raised by UBS Group AG from $70.00 to $90.00. They now have a “buy” rating on the stock.
• 3/12/2026 – AnaptysBio had its price target raised by Wedbush from $60.00 to $75.00. They now have an “outperform” rating on the stock.

Insider Activity at AnaptysBio

In other AnaptysBio news, CEO Daniel Faga sold 17,679 shares of AnaptysBio stock in a transaction on Friday, March 27th. The shares were sold at an average price of $61.61, for a total transaction of $1,089,203.19. Following the completion of the sale, the chief executive officer owned 495,965 shares of the company’s stock, valued at approximately $30,556,403.65. The trade was a 3.44% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Eric J. Loumeau sold 10,000 shares of AnaptysBio stock in a transaction on Wednesday, February 11th. The stock was sold at an average price of $54.00, for a total transaction of $540,000.00. Following the sale, the insider directly owned 12,835 shares of the company’s stock, valued at $693,090. This represents a 43.79% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 48,324 shares of company stock valued at $2,787,594 over the last quarter. Corporate insiders own 33.50% of the company’s stock.

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.